Terms: = Prostate cancer AND ERG, P11308, 2078 AND Staging
9 results:
1. The relevance of erg immunoexpression intensity for prostatic adenocarcinoma in radical prostatectomy of 635 samples.
Feitosa PMFA; Hirth CG; Silva-Fernandes IJL; Dornelas CA
APMIS; 2023 Sep; 131(9):465-471. PubMed ID: 37439391
[TBL] [Abstract] [Full Text] [Related]
2. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical prostatectomy for High-risk prostate cancer.
Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
[TBL] [Abstract] [Full Text] [Related]
3. Differences in prostate cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different?
Zhou CD; Pettersson A; Plym A; Tyekucheva S; Penney KL; Sesso HD; Kantoff PW; Mucci LA; Stopsack KH
Cancer Prev Res (Phila); 2022 Dec; 15(12):815-825. PubMed ID: 36125434
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of Intense Androgen Deprivation Before prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
McKay RR; Ye H; Xie W; Lis R; Calagua C; Zhang Z; Trinh QD; Chang SL; Harshman LC; Ross AE; Pienta KJ; Lin DW; Ellis WJ; Montgomery B; Chang P; Wagner AA; Bubley GJ; Kibel AS; Taplin ME
J Clin Oncol; 2019 Apr; 37(11):923-931. PubMed ID: 30811282
[TBL] [Abstract] [Full Text] [Related]
5. prostate Specific Antigen as a Tumor Marker in prostate cancer: Biochemical and Clinical Aspects.
Salman JW; Schoots IG; Carlsson SV; Jenster G; Roobol MJ
Adv Exp Med Biol; 2015; 867():93-114. PubMed ID: 26530362
[TBL] [Abstract] [Full Text] [Related]
6. Future prospects in the diagnosis and management of localized prostate cancer.
Tefekli A; Tunc M
ScientificWorldJournal; 2013; 2013():347263. PubMed ID: 24163619
[TBL] [Abstract] [Full Text] [Related]
7. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:erg models.
Whelan C; Kawachi M; Smith DD; Linehan J; Babilonia G; Mejia R; Wilson T; Smith SS
J Urol; 2014 Jan; 191(1):220-6. PubMed ID: 23669563
[TBL] [Abstract] [Full Text] [Related]
8. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-erg fusion gene.
Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
[TBL] [Abstract] [Full Text] [Related]
9. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer.
Ishkanian AS; Zafarana G; Thoms J; Bristow RG
Acta Oncol; 2010 Oct; 49(7):888-94. PubMed ID: 20590366
[TBL] [Abstract] [Full Text] [Related]
